Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

905
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
905
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.5K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

718
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
718
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

1.2K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
1.2K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

741
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.

Human molecular genetics·2015
Same author

Human somatic stem cell-based therapy for cartilage regeneration.

Annals of translational medicine·2015
Same author

Allogeneic Neural Stem/Progenitor Cells Derived From Embryonic Stem Cells Promote Functional Recovery After Transplantation Into Injured Spinal Cord of Nonhuman Primates.

Stem cells translational medicine·2015
Same author

Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage.

Molecular brain·2015
Same author

Muscle Satellite Cell Protein Teneurin-4 Regulates Differentiation During Muscle Regeneration.

Stem cells (Dayton, Ohio)·2015
Same author

The Musashi family RNA-binding proteins in stem cells.

Biomolecular concepts·2015

Related Experiment Video

Updated: Jan 3, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.0K

[Ropinirole Hydrochloride for ALS].

Shinichi Takahashi1, Satoru Morimoto, Komei Fukushima

  • 1Department of Neurology and Stroke, Saitama medical university International medical center.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|November 14, 2019
PubMed
Summary

Ropinirole hydrochloride shows promise in preventing motor neuron death in ALS patients. A clinical trial is evaluating its safety and efficacy, using patient-derived stem cells to guide drug development for ALS.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K

Related Experiment Videos

Last Updated: Jan 3, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.0K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.2K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K

Area of Science:

  • Neuroscience
  • Stem Cell Biology
  • Drug Discovery

Background:

  • Motor neuron degeneration is a hallmark of Amyotrophic Lateral Sclerosis (ALS).
  • Induced-pluripotent stem cells (iPSCs) from ALS patients can model disease-specific processes in vitro.
  • A previous study identified ropinirole hydrochloride as a compound that prevents motor neuron death.

Purpose of the Study:

  • To assess the safety and tolerability of ropinirole hydrochloride extended-release tablets in ALS patients.
  • To evaluate the efficacy of ropinirole hydrochloride in slowing ALS progression.
  • To validate iPSC-based drug development strategies for ALS.

Main Methods:

  • An ongoing Phase I/IIa randomized, double-blind, placebo-controlled clinical trial.
  • Testing ropinirole hydrochloride extended-release tablets in patients with clinically diagnosed ALS.
  • Utilizing patient-derived iPSCs and motor neurons for efficacy evaluation.

Main Results:

  • Ropinirole hydrochloride was identified as a potential therapeutic agent preventing motor neuron death in preclinical models.
  • The clinical trial is currently underway to determine safety, tolerability, and efficacy.
  • Patient-derived iPSCs successfully recapitulated disease-specific pathophysiological processes.

Conclusions:

  • Ropinirole hydrochloride is a potential candidate for slowing ALS progression.
  • The clinical trial serves as a critical test for iPSC-based drug development strategies.
  • Further results are anticipated to guide future ALS therapeutic interventions.